September 1, 2022 | Issue #16

In this week's newsletter:

🍷 Sneaky spirits

🤝 A landmark DeSci partnership?

👀 New CDC life expectancy data

🌐 Weekend reading material

An Unbiased Look at Alcohol’s Effect on Longevity

We’ve heard it throughout our lives...“This woman lived to be 110 because of whiskey...”“A glass of red wine a night is good for your heart.”Others even tout moderate drinking as a way to lower your risk of Type 2 diabetes and some types of depression. After a quick Google Search, you may also find that drinking can reduce your risk of developing and dying from heart disease too!Over the years, you see, we’ve seen a number of researchers touting the health benefits of wine and the modest consumption of alcohol. This has led to confusion for consumers and clinicians alike, sparking several conflicting opinions along the way.To get closer to the truth, though, today we’re diving deep into the recent studies on alcohol’s effects on longevity, mortality, and whether moderate alcohol intake is the healthful supplement some claim it is.Is it possible that even an occasional indulgence impacts lifespan drastically? Let's Find Out >>

The chat boards were spinning this week after news broke of Pfizer's "interest" in making its first foray into longevity research and Decentralized Science (DeSci).The biggest of Big Pharma, through its ventures arm, has applied to VitaDAO's Institutional Genesis Raise, proposing to contribute $500,000 to VitaDAO and participate in the governance of VitaDAO using VITA tokens.Now, Pfizer in the same sentence as "decentralized" may be a headscratcher...But the fact that their eyes are finally on aging is a promising sign, further solidifying, as Pfizer Ventures' Executive Director Michael Baran puts it, that the field of longevity is approaching "a pivotal moment in history."📌 You can read the submission from Pfizer Ventures here.

• BioAge Partners With Age Labs to Decipher Healthy Longevity Using Samples and Data From a Preeminent Northern European Biobank

• Mayo Clinic announces a strategic collaboration for a new era of biomanufacturing

• Turn Bio announces a new director in its search for therapies to cure eye diseases; falling on the heels of co-founder Vittorio Sebastiano, PhD, becoming head of research

• ElevateBio Partners with the California Institute for Regenerative Medicine to Accelerate the Development of Regenerative Medicines

• InVivo Biosystems and Thaena Announce Novel Metabolite Research Platform With Compelling Longevity and Healthspan Implications and Outcomes

• MAIA Biotechnology Reports Second Quarter 2022 Financial Results and Provides Corporate Update

• U.S. life expectancy drops sharply, the second consecutive decline (STAT News)

• Letter from Editors-in-Chief of Aging Cell announcing their resignations due to issues in running the journal (Twitter)

• Looking old before your time? Your smartphone’s blue light may be to blame (Fast Company)

• Here’s how much Americans have saved for retirement at every age (CNBC)

• Scientists Move Closer to Unlocking the Secrets of the Immortal Jellyfish, and Possibly Human Aging (WSJ)

• Impetus Grants: Round 2 Results and collaboration with Hevolution

• Hevolution Foundation and AFAR Announce New Investigator Awards in Aging Biology and Geroscience Research

Performance:

Latest Price: $130.337d-Return: +1.85Market Cap: $11.11b

Key Drivers:

Denali (DNLI): -10.46%Geron (GERN): +12.61%Miromatrix (MIRO): +35.46%